NCT01689870View on ClinicalTrials.gov

Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

August 31, 2014

Conditions
Metastatic Melanoma
Interventions
DRUG

Anti-OX40

Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5

DRUG

Ipilimumab

Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1

Sponsors

Collaborators (1)

AgonOx
All Listed Sponsors
collaborator

AgonOx

INDUSTRY

lead

Ludwig Institute for Cancer Research

OTHER